Company

Perceive Pharma, Inc.

Perceive Pharma develops small molecule neuroprotective treatments for ophthalmic diseases.

About

Perceive Pharma develops small molecule neuroprotective therapeutics for ophthalmic diseases, with a focus on glaucoma. Its lead candidate, PBI-671, targets glaucoma, and the company uses proprietary screening technology to identify neuroprotective pathways. Founded in 2023 as a spin-off from Perceive Biotherapeutics, the company is based in San Francisco, US. In February 2025, it raised USD 15 million in Series A funding from Braidwell, Catalio Capital Management, Deerfield Management, Johnson & Johnson Innovation, GV and Retinal Degeneration Fund.

1Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in